what this node claims
AlphaFold metrics / CXCR4
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
53%
low debt pressure
21%
82%structurestrong
pLDDT 82.26
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- confident
- confidence pct
- 82.26
- coverage context
- missing or not linked
- interpretation
- usable fold context with explicit model-confidence limits
- pae context
- missing or not linked
- plddt avg
- 82.26
- sequence length
- 0
AlphaFold metrics visual
Confident backbone model
352 residues / min 31.7 / max 98.5 / source alphafold db
Very high
57.4%
202 residues / >=90
Confident
21.6%
76 residues / 70-89
Low
8.2%
29 residues / 50-69
Very low
12.8%
45 residues / <50
usable fold context with explicit model-confidence limits
Near-complete coverage / observed 352 of 352 residues.
- residues 320-352 / mean 48.4
- residues 1-26 / mean 39.48
- residues 304-310 / mean 63.5
- residues 29-34 / mean 63.78
proof debt register
21%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.